TY - JOUR
T1 - Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes
AU - Pan, Wei
AU - Yu, Jingjia
AU - Shi, Ruizheng
AU - Yan, Lei
AU - Yang, Tianlun
AU - Li, Yuanjian
AU - Zhang, Zhuohua
AU - Yu, Guolong
AU - Bai, Yongping
AU - Schuchman, Edward H.
AU - He, Xingxuan
AU - Zhang, Guogang
PY - 2014/5
Y1 - 2014/5
N2 - BACKGROUND: Although there are several reported evidences for a pathogenic role of sphingolipid signaling in atherosclerosis, peripheral blood levels of ceramide and secretory acid sphingomyelinase (S-SMase) activity in patients with acute coronary syndromes (ACS) have not been evaluated. METHODS AND RESULTS: A total of 304 CAD patients and 52 healthy individuals were divided into four groups: control group (n=52), stable angina pectoris (SAP) group (n=98), unstable angina pectoris (UAP) group (n=92), and acute myocardial infarction (AMI) group (n=114). Plasma levels of sphingomyelin (SPM) were elevated in patients with UAP and AMI compared with those in the control and SAP participants. Plasma ceramide levels and S-SMase activity in patients with ACS (including UAP and AMI) on day 0 were significantly higher than those in the control and SAP participants. Elevation in plasma ceramide levels in patients with UAP and AMI was sustained until a day after percutaneous coronary intervention or day 7, respectively. Moreover, in patients with UAP, S-SMase activity elevation on day 0 was followed by a gradual decrease toward the SAP range up to a day after percutaneous coronary intervention. In patients with AMI, elevation in S-SMase activity showed a peak on day 3. CONCLUSION: Serial changes in plasma ceramide and S-SMase activity were documented in patients with ACS. These findings provide an insight into the molecular mechanism of plaque destabilization.
AB - BACKGROUND: Although there are several reported evidences for a pathogenic role of sphingolipid signaling in atherosclerosis, peripheral blood levels of ceramide and secretory acid sphingomyelinase (S-SMase) activity in patients with acute coronary syndromes (ACS) have not been evaluated. METHODS AND RESULTS: A total of 304 CAD patients and 52 healthy individuals were divided into four groups: control group (n=52), stable angina pectoris (SAP) group (n=98), unstable angina pectoris (UAP) group (n=92), and acute myocardial infarction (AMI) group (n=114). Plasma levels of sphingomyelin (SPM) were elevated in patients with UAP and AMI compared with those in the control and SAP participants. Plasma ceramide levels and S-SMase activity in patients with ACS (including UAP and AMI) on day 0 were significantly higher than those in the control and SAP participants. Elevation in plasma ceramide levels in patients with UAP and AMI was sustained until a day after percutaneous coronary intervention or day 7, respectively. Moreover, in patients with UAP, S-SMase activity elevation on day 0 was followed by a gradual decrease toward the SAP range up to a day after percutaneous coronary intervention. In patients with AMI, elevation in S-SMase activity showed a peak on day 3. CONCLUSION: Serial changes in plasma ceramide and S-SMase activity were documented in patients with ACS. These findings provide an insight into the molecular mechanism of plaque destabilization.
KW - acute coronary syndromes
KW - ceramide
KW - matrix metalloproteinase
KW - secretory acid sphingomyelinase
KW - sphingomyelin
KW - sphingomyelinase
KW - tumor necrosis factor
UR - https://www.scopus.com/pages/publications/84898539271
U2 - 10.1097/MCA.0000000000000079
DO - 10.1097/MCA.0000000000000079
M3 - Article
C2 - 24589572
AN - SCOPUS:84898539271
SN - 0954-6928
VL - 25
SP - 230
EP - 235
JO - Coronary Artery Disease
JF - Coronary Artery Disease
IS - 3
ER -